BioPharma Dive1 min read
saveSanofi gains FDA clearance for Gaucher disease pill
The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.
The approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.
comments(0)
5-min edit window · permanent after that